Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 18;2(3):77-84.
doi: 10.1016/j.ijwd.2016.05.001. eCollection 2016 Sep.

A dermatologist guide to immunogenicity

Collin M Blattner  1 , Soham P Chaudhari  2 , John Young 3rd  3 , Jenny E Murase  4   5
Affiliations
Review

A dermatologist guide to immunogenicity

Collin M Blattner et al. Int J Womens Dermatol. .

Abstract

Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug. To combat this phenomenon, low-dose immunomodulators may be used in hopes of preventing autoantibodies. We review the current literature and provide a basic treatment algorithm for patients with moderate to severe psoriasis.

Keywords: HACA antibodies; antidrug antibodies; autoantibodies; biologic fatigue; resistance to biologics.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Basic treatment algorithm for moderate to severe psoriasis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Adişen E, Aral A, Aybay C, Gürer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study. J Dermatol. 2010;37(8):708–713. - PubMed
    1. Aksu K, Cagirgan S, Ozsan N, Keser G, Sahin F. Non-Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis. Rheumatol Int. 2011;31(12):1645–1647. - PubMed
    1. Antoniou C, Dessinioti C, Vergou T, Stratigos AJ, Avgerinou G, Kostaki M. Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis. J Eur Acad Dermatol Venereol. 2010;24(12):1413–1420. - PubMed
    1. Baert F, De Vos M, Louis E. Vermeire S; Belgian IBD Research Group. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol Belg. 2007;70(2):163–170. - PubMed
    1. Bardazzi F, Odorici G, Virdi A, Antonucci VA, Tengattini V, Patrizi A. Autoantibodies in psoriatic patients treated with anti-TNF-α therapy. J Dtsch Dermatol Ges. 2014;12(5):401–406. - PubMed